Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
14 evidence topics · 12 sources
Summary
- The NDA under FDA review proposes varegacestat “for the treatment of adults with desmoid tumors”.
- The Desmoid Tumor Working Group considers active surveillance the first step after diagnosis in the majority of patients and proposes active treatment only in case of persistent progression. Treatment choice is guided by anatomical site: surgery remains the first option at progression for abdominal wall tumors, systemic therapy is the first option for intra-abdominal, retroperitoneal, and pelvic tumors, and medical therapy is preferred for extremity, girdle, and chest wall tumors and is first line for head and neck and intrathoracic tumors. The group states that no definitive sequence of systemic treatments can be proposed because comparative studies are lacking.
- The 2023 global consensus update addressed the positioning of gamma secretase inhibitors, with nirogacestat the first approved drug for desmoid tumors. NCCN soft tissue sarcoma guidelines version 1.2025, as quoted in a Cigna coverage policy, list Ogsiveo and sorafenib as category 1 and methotrexate-based, imatinib, pazopanib, and doxorubicin-based regimens as category 2A.
- The approved gamma secretase inhibitor, OGSIVEO (nirogacestat), is indicated for adult patients with progressing desmoid tumors who require systemic treatment, at 150 mg orally twice daily until disease progression or unacceptable toxicity. NICE recommends nirogacestat within its marketing authorisation; in its appraisal, current options in England are off-label chemotherapy, off-label tyrosine kinase inhibitors, and surgery, and nirogacestat is expected to displace chemotherapy and best supportive care.
- RINGSIDE Part B enrolled 156 participants with progressive disease (tumor growth of at least 20% within the past 12 months) who were either treatment-naïve with tumors not amenable to surgery or had refractory or recurrent disease after at least one line of therapy.
- Immunome states that systemic therapy is recommended for about 75% of tumors after progression during initial active surveillance, that gamma secretase inhibitors “may ultimately capture much of the market for desmoid tumor therapy”, and that it aims to “Become Standard of Care treatment of Desmoid Tumors”. It describes varegacestat as oral and once daily, estimates “10-11k Actively Managed Patients (US)”, and anticipates that patients may receive about 1.5 to 2 years of treatment, pause, and return for treatment.
- Immunome plans to commercialize in the United States through a targeted sales force designed to reach specialized treatment centers, and its corporate presentation names about 85 sarcoma centers of excellence.
Proposed indication under FDA review
Active surveillance as the first step and active treatment after persistent progression
“An initial watchful waiting approach is useful to document actual tumor progression. Active therapies need to be individualized on a multidisciplinary basis for patients with clearly progressing disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment choice by anatomical site in the global consensus algorithm
Positioning of gamma secretase inhibitors in the 2023 global consensus update
“The 2023 update of the global evidence-based consensus guideline focused on the positioning of local therapies alongside surgery and radiotherapy in the treatment algorithm as well as the positioning of the newest class of medical agents, such as γ-secretase inhibitors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 2023 consensus guideline is informed by a number of new aspects, including data for local ablative therapies such as cryotherapy; other indications for surgery; and the γ-secretase inhibitor nirogacestat, the first representative of the newest class of medical agents and first approved drug for DT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote